Eyepoint Pharmaceuticals Inc (EYPT)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Eyepoint Pharmaceuticals Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 10 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 12.30 $ — 28% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
4 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years -8.8% failed
- More than 10% revenue growth is expected for the coming year 2,888.0% passed
- Share count grows by less than 3% a year 25.2% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") -803.4% failed
- Gross margin at 40% or higher and without meaningful erosion 93.4% passed
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA 283 m net cash passed
- Operating cash flow covers the profits of the last three years 69 m failed
- Return on capital at 15% or higher, or up versus two years ago -74.5% failed
- Insiders hold at least 10% or are net buyers 3.7% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 229.3% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 13
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -3.55 | -4.09 – -2.69 | 2 | -12.1% | 12 |
| 12/31/2027 | -3.04 | -4.60 – -1.74 | 33 | 14.4% | 12 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.92 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.64 | – | 12 | -17.40 | -357.30 | -36 | -36 |
| 2025: Q1 | -0.65 | – | 25 | 109.30 | -184.80 | -53 | -53 |
| 2025: Q2 | -0.85 | – | 5 | -43.70 | -1,114.30 | -63 | -64 |
| 2025: Q3 | -0.85 | – | 1 | -90.80 | -6,183.40 | -59 | -60 |
| 2025: Q4 | -0.81 | – | 1 | -94.60 | -10,904.70 | -65 | -66 |
| 2026: Q1 | -0.99 | – | 1 | -97.20 | -12,188.50 | -81 | -82 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 2 | -22 | -22 | -6.81 | -16 | 21 | 32 |
| 2017 | 8 | -19 | -18 | -5.23 | -20 | 13 | 19 |
| 2018 | 3 | -26 | -53 | -11.50 | -22 | 12 | 72 |
| 2019 | 20 | -48 | -57 | -5.44 | -57 | 8 | 73 |
| 2020 | 34 | -37 | -45 | -3.54 | -14 | 19 | 92 |
| 2021 | 37 | -55 | -58 | -2.03 | -50 | 184 | 263 |
| 2022 | 41 | -100 | -102 | -2.74 | -65 | 96 | 180 |
| 2023 | 46 | -75 | -71 | -1.82 | 2 | 266 | 355 |
| 2024 | 43 | -146 | -131 | -2.32 | -126 | 337 | 418 |
| 2025 | 31 | -243 | -232 | -3.17 | -240 | 306 | 364 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
EyePoint, Inc. beschäftigt sich mit der Entwicklung und Vermarktung von Therapeutika zur Verbesserung des Lebens von Patienten mit schweren Netzhauterkrankungen.
| CEO Insider Trades (12 Mo.) | buying own stock |
|---|---|
| Employees | 214 |
| Headquarters | Watertown, MA |
| Address | 480 Pleasant Street, 02472 Watertown, United States |
| Phone | 617 926 5000 |
| Website | eyepoint.bio |
| IPO Date | 27. Jan 2005 |
| ISIN | US30233G2093 |
| Stock Split | 1:10 on 12/09/2020 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Jay S. Duker M.D. | President, CEO & Director | 1959 |
| George O. Elston CPA | Executive VP & CFO | 1965 |
| Ramiro Ribeiro M.D., Ph.D. | Chief Medical Officer | 1983 |
| Marcia Sellos-Moura Ph.D. | Chief Scientific Officer | – |
| Ron I. Honig Esq. | Chief Legal Officer & Company Secretary | – |
| Jennifer Leonard | Chief People Officer & Senior VP of IT | – |
| David Scott Jones M.A. | Senior Vice President | 1968 |
| Isabelle Lefebvre | Chief Regulatory Officer | – |
| Michael J. Maciocio | Chief Manufacturing Officer | – |
| Michael Campbell | Chief Commercial Officer | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 10. Jul 2026 | Duker Jay S. | President and CEO | Other | 8,059 | 14.72 | 118,628 |
| 10. Jul 2026 | Duker Jay S. | President and CEO | Other | 16,667 | 0.00 | – |
| 17. Apr 2026 | Ramiro Ribeiro | Insider | Sell | 2,437 | 15.00 | 36,555 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.